Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Last updated: October 13, 2025
Sponsor: Perceive Biotherapeutics, Inc.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Aging

Macular Degeneration

Geographic Atrophy

Treatment

VOY-101

Clinical Study ID

NCT06087458
PBI-AMD-002
  • Ages > 60
  • All Genders

Study Summary

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are ≥60 years of age at the time of consent.

  • Are willing and able to understand and provide written informed consent.

  • Are willing and able to return for scheduled treatment and follow-up examinations.

  • Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.

  • Well-demarcated GA secondary to AMD in the absence of MNV and in the absence ofhistory of MNV for both eyes.

  • Absence of signs of non-exudative MNV.

  • Additional Ocular Inclusion Criteria for both eyes.

  • Meet certain genotype criteria for risk of AMD.

Exclusion

Exclusion Criteria:

  • Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use anddocument use of effective contraception for the duration of the study.

  • Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: VOY-101
Phase: 1/2
Study Start date:
June 21, 2023
Estimated Completion Date:
March 31, 2028

Study Description

This is a prospective, open-label, multi-center Phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of escalating dose levels of VOY-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (AMD).

Connect with a study center

  • Sydney Retina Clinic and Day Surgery

    Sydney, New South Wales 2000
    Australia

    Site Not Available

  • Sydney Retina Clinic and Day Surgery

    Sydney 2147714, New South Wales 2155400 2000
    Australia

    Site Not Available

  • Cerulea Clinical Trials

    East Melbourne, Victoria 3002
    Australia

    Site Not Available

  • Cabrini Research

    Melbourne, Victoria 3144
    Australia

    Site Not Available

  • Centre for Eye Research Australia (CERA)

    Melbourne, Victoria 3002
    Australia

    Site Not Available

  • Cerulea Clinical Trials

    East Melbourne 6952201, Victoria 2145234 3002
    Australia

    Site Not Available

  • Rambam Medical Center

    Haifa,
    Israel

    Site Not Available

  • Rambam Medical Center

    Haifa 294801,
    Israel

    Active - Recruiting

  • Tel-Aviv Sourasky Medical Center, Ophthalmology Division

    Tel Aviv, 64239
    Israel

    Site Not Available

  • Tel-Aviv Sourasky Medical Center, Ophthalmology Division

    Tel Aviv 293397, 64239
    Israel

    Active - Recruiting

  • Retina Macula Institute of AZ

    Scottsdale 5313457, Arizona 5551752 85255
    United States

    Active - Recruiting

  • The Retina Partners

    Encino 5346649, California 5332921 91436
    United States

    Active - Recruiting

  • Retinal Consultants Medical Group

    Sacramento 5389489, California 5332921 95825
    United States

    Active - Recruiting

  • Retina Consultants San Diego

    San Diego 5391811, California 5332921 92064
    United States

    Active - Recruiting

  • Star Retina

    Burleson 4677551, Texas 4736286 76028
    United States

    Active - Recruiting

  • Retina Center of Texas

    Southlake 4733313, Texas 4736286 76092
    United States

    Active - Recruiting

  • University of Utah John A. Moran Eye Center

    Salt Lake City 5780993, Utah 5549030 84132
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.